RCUS logo

RCUS
Arcus Biosciences Inc

1,781
Mkt Cap
$2.88B
Volume
1.58M
52W High
$26.40
52W Low
$6.50
PE Ratio
-6.96
RCUS Fundamentals
Price
$22.96
Prev Close
$21.84
Open
$21.95
50D MA
$21.46
Beta
1.49
Avg. Volume
1.3M
EPS (Annual)
-$3.29
P/B
4.56
Rev/Employee
$410,981.70
$1,776.34
Loading...
Loading...
News
all
press releases
Arcus Biosciences (NYSE:RCUS) Trading 5.4% Higher Following Analyst Upgrade
Arcus Biosciences (NYSE:RCUS) Shares Up 5.4% After Analyst Upgrade...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $41.00
Wedbush increased their price target on Arcus Biosciences from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Thursday...
MarketBeat·3d ago
News Placeholder
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twelve ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold...
MarketBeat·11d ago
News Placeholder
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and...
Business Wire·12d ago
News Placeholder
Hudson Bay Capital Management LP Has $4.62 Million Stake in Arcus Biosciences, Inc. $RCUS
Hudson Bay Capital Management LP decreased its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 20.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 340,000 shares of the company's stock after selling 90,000 shares during the...
MarketBeat·14d ago
News Placeholder
Arcus Biosciences, Inc. $RCUS Shares Bought by Decheng Capital LLC
Decheng Capital LLC raised its stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 242.3% in the 3rd quarter, according to the company in its most recent filing with the Securities...
MarketBeat·20d ago
News Placeholder
WINTON GROUP Ltd Purchases Shares of 92,229 Arcus Biosciences, Inc. $RCUS
WINTON GROUP Ltd acquired a new position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and...
MarketBeat·24d ago
News Placeholder
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and...
Business Wire·27d ago
News Placeholder
Citigroup Raises Arcus Biosciences (NYSE:RCUS) Price Target to $45.00
Citigroup boosted their target price on shares of Arcus Biosciences from $44.00 to $45.00 and gave the stock a "buy" rating in a research report on Thursday...
MarketBeat·1mo ago
News Placeholder
Arcus Biosciences (NYSE:RCUS) Stock Price Expected to Rise, Leerink Partners Analyst Says
Leerink Partners upped their price target on shares of Arcus Biosciences from $36.00 to $49.00 and gave the company an "outperform" rating in a research note on Monday...
MarketBeat·1mo ago
<
1
2
...
>

Latest RCUS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.